Antiphospholipid antibodies and growth retardation in intrauterine development

L C J F Spegiorin1, E A Galão, J M P De Godoy

  • 1Department of the Gynaecology and Obstetrics of the Medical School, São José do Rio Preto, SP, Brazil.

Prague Medical Report
|January 30, 2008
PubMed

Insights

Prophylaxis with low-dose heparin and aspirin did not prevent intrauterine growth restriction or low birth weights in antiphospholipid antibody syndrome patients. This indicates continued risks for newborns despite treatment.

Area of Science:

  • Obstetrics and Gynecology
  • Immunology
  • Perinatology

Background:

  • Antiphospholipid antibody syndrome (APS) is linked to adverse pregnancy outcomes, including intrauterine growth restriction (IUGR) and low birth weight (LBW).
  • Prophylactic treatment with heparin and aspirin is a common strategy, but its efficacy in preventing these complications in APS patients requires further evaluation.

Purpose of the Study:

  • To assess the effectiveness of low-dose unfractionated heparin and aspirin prophylaxis in preventing IUGR and LBW in pregnant women with APS.

Main Methods:

  • A prospective study evaluated 34 gestations in 28 women with APS and a history of recurrent miscarriages, comparing outcomes to a control group of 39 women.
  • Diagnosis of APS involved ELIZA tests for IgG/IgM antiphospholipid antibodies and activated partial thromboplastin time (aPTT) for lupus anticoagulant.
  • Treatment group received daily low-dose aspirin (100 mg) and twice-daily low-dose subcutaneous heparin (5000 IU).

Main Results:

  • The study group (APS patients) exhibited a statistically significant higher incidence of IUGR and LBW compared to the control group.
  • Despite prophylactic treatment with heparin and aspirin, newborns in the APS group were still at increased risk for growth abnormalities.

Conclusions:

  • Prophylactic low-dose unfractionated heparin and aspirin therapy is not fully effective in preventing intrauterine growth restriction and low birth weights in pregnancies affected by antiphospholipid antibody syndrome.
  • Children born to mothers with APS remain at elevated risk for these adverse outcomes, even with standard prophylactic measures.

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Transcytosis of IgG01:15

Transcytosis of IgG

Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...